Erschienen in:
01.09.2011 | Research Letter
Plasma procalcitonin and risk of type 2 diabetes in the general population
verfasst von:
A. Abbasi, E. Corpeleijn, D. Postmus, R. T. Gansevoort, P. E. de Jong, R. O. B. Gans, J. Struck, H. L. Hillege, R. P. Stolk, G. Navis, S. J. L. Bakker
Erschienen in:
Diabetologia
|
Ausgabe 9/2011
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: Chronic low-grade inflammation is a key feature of the pathophysiology of obesity, insulin resistance and type 2 diabetes [
1]. In vitro studies have found that parenchymal cells of tissues, including adipocytes, secrete procalcitonin in response to stimulation by activated macrophages [
2]. Since obesity is associated with an increased presence of activated macrophages in adipose tissue, a similar scenario may play a role in vivo [
2,
3]. In an initial study, we found that procalcitonin is associated with insulin resistance and all components of the metabolic syndrome [
3]. Our current aim is to test the prospective association of plasma procalcitonin with incident type 2 diabetes in the general population, and to compare its predictive value with that of high sensitivity C-reactive protein (hs-CRP). …